logo
logo

Nuclide Therapeutics raises €5.7 million in a seed round led by Marathon Beteiligungs AG to develop drugs targeting treatment-resistant cancers.

Sep 22, 2025•14 days ago

Amount Raised

€5.7 Million

Round Type

Seed

LondonTherapeuticsMedicalBiotechnologyHealth Care

Investors

Marathon Beteiligungs Ag

Description

Nuclide Therapeutics, a spinout from King's College London, has closed a seed funding round of €5.7 million led by Marathon Beteiligungs AG. The company aims to create radioactive drugs for treating therapy-resistant cancers. Their technology focuses on targeting specific cell pathways linked to drug resistance. This approach aims to improve the efficacy of cancer treatment by delivering targeted therapy directly to resistant cells.

Company Information

Company

Nuclide Therapeutics

Location

London, England, United Kingdom

About

Nuclide Therapeutics is a King’s College London spinout developing radioactive drugs to target therapy-resistant cancers. The company focuses on targeting ALDH1A1, an enzyme exploited by treatment-resistant cancers. Their innovative approach combines detection with treatment, allowing for specific targeting of resistant tumor cells. Nuclide aims to improve outcomes for cancer patients, particularly in lung cancer treatment.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers